

REMARKS

After entry of this amendment, claims 1-13, 17-20 and 32-34 are pending. Claims 5, 9, 10, 18, 32, and 33 have been additionally amended.

Applicants elected a single nucleotide sequence and Group in the prior restriction. Applicants incorrectly identified the nucleic acid identifier that corresponds to the polypeptide sequence of SEQ ID NO: 6352. The correct sequence identifier is SEQ ID NO: 2580 and not SEQ ID NO: 1450. Accordingly, Applicants have amended the claims to recite SEQ ID NO: 2580. For the record, Applicants meant to elect SEQ ID NO: 2580 and not SEQ ID NO: 1450. Applicants also amended claim 18 to recite "An immunogenic composition" for proper antecedent basis.

The amendments to the claims are not believed to introduce any prohibited new matter. Additionally, Applicants maintain the right to pursue the subject matter of SEQ ID NO: 1450 and its counterpart polypeptide in a divisional application.


CONCLUSION

Should the Examiner have any questions or comments regarding Applicants' amendments or response, (s)he is asked to contact Applicants' undersigned representative. Please direct all correspondence to the below-listed address.

In the event that the Office believes that there are fees outstanding in the above-referenced matter and for purposes of maintaining pendency of the application, the Office is authorized to charge the outstanding fees to Deposit Account No. 50-0573. The Office is likewise authorized to credit any overpayment to the same Deposit Account Number. The undersigned is signing in her authority under 37 C.F.R. § 1.34(b).

Date: August 18, 2005

Respectfully submitted,



Mercedes K. Meyer, Ph.D., Esq.
Registration No. 44,939
DRINKER BIDDLE & REATH LLP
1500 K Street, N.W., Suite 1100
Washington, D.C. 20005-1209
Tel: (202) 842-8821/Fax: (202) 842 8465